PE20130640A1 - Compuestos heterociclicos, su preparacion y su aplicacion terapeutica - Google Patents
Compuestos heterociclicos, su preparacion y su aplicacion terapeuticaInfo
- Publication number
- PE20130640A1 PE20130640A1 PE2012002466A PE2012002466A PE20130640A1 PE 20130640 A1 PE20130640 A1 PE 20130640A1 PE 2012002466 A PE2012002466 A PE 2012002466A PE 2012002466 A PE2012002466 A PE 2012002466A PE 20130640 A1 PE20130640 A1 PE 20130640A1
- Authority
- PE
- Peru
- Prior art keywords
- pyridin
- compounds
- triazolo
- chloro
- phenol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE A ES FENILO; B ES FENILO, PIRIDINA O PIRIMIDINA; R1 Y R2 SON CADA UNO H, OH O HALOGENO; R3, R4 Y R5 SON CADA UNO H, O-ALQUILO(C1-C6), OH, HETEROCICLOALQUIL-(CH2)n-OH, ENTRE OTROS, EN DONDE n ES DE 1 A 3; R6 ES H, O-ALQUILO(C1-C6) O ALQUILO(C1-C6); X ES N O C; Y ES CH O UN ENLACE COVALENTE. SON COMPUESTOS PREFERIDOS: 4-CLORO-3-[2-(PIRIDIN-3-ILAMINO)-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-6-IL]-FENOL; 4-CLORO-3-[2-(PIRIMIDIN-5-ILAMINO)-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-6-IL]-FENOL; 4-CLORO-3-[2-(5-HIDROXIMETIL-PIRIDIN-3-ILAMINO)-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-6-IL]-FENOL; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE QUINASA Src SIENDO UTILES EN EL TRATAMIENTO DE EDEMA RETINIANO, DEGENERACION MACULAR, RETINOPATIA DIABETICA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10305665 | 2010-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20130640A1 true PE20130640A1 (es) | 2013-03-30 |
Family
ID=43033247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2012002466A PE20130640A1 (es) | 2010-06-22 | 2011-06-22 | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica |
Country Status (27)
Country | Link |
---|---|
US (1) | US20130123271A1 (es) |
EP (1) | EP2585439A1 (es) |
JP (1) | JP2013533237A (es) |
KR (1) | KR20130116070A (es) |
CN (1) | CN103140480A (es) |
AR (1) | AR081960A1 (es) |
AU (1) | AU2011268938A1 (es) |
BR (1) | BR112012032721A2 (es) |
CA (1) | CA2803496A1 (es) |
CL (1) | CL2012003637A1 (es) |
CO (1) | CO6660505A2 (es) |
CR (1) | CR20120653A (es) |
DO (1) | DOP2012000317A (es) |
EA (1) | EA201291329A1 (es) |
EC (1) | ECSP12012354A (es) |
GT (1) | GT201200345A (es) |
IL (1) | IL223721A0 (es) |
MA (1) | MA34384B1 (es) |
MX (1) | MX2012015305A (es) |
NI (1) | NI201200193A (es) |
NZ (1) | NZ605022A (es) |
PE (1) | PE20130640A1 (es) |
SG (1) | SG186424A1 (es) |
TN (1) | TN2012000610A1 (es) |
TW (1) | TW201204723A (es) |
UY (1) | UY33461A (es) |
WO (1) | WO2011161159A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
WO2014195276A1 (en) * | 2013-06-07 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Substituted triazolopyridines having activity as mps-1 inhibitors |
CA2914668A1 (en) * | 2013-06-10 | 2014-12-18 | Volker Schulze | Novel compounds for the treatment of cancer |
NZ733135A (en) | 2014-12-24 | 2018-06-29 | Gilead Sciences Inc | Fused pyrimidine compounds for the treatment of hiv |
TW202237569A (zh) | 2014-12-24 | 2022-10-01 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
BR112017013440A2 (pt) | 2014-12-24 | 2018-01-09 | Gilead Sciences, Inc. | compostos de isoquinolina para o tratamento de hiv |
US10894784B2 (en) | 2015-12-18 | 2021-01-19 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
US10265315B2 (en) | 2016-04-08 | 2019-04-23 | Baylor College Of Medicine | Small molecule regulators of steroid receptor coactivators and methods of use thereof |
WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
WO2021254464A1 (zh) * | 2020-06-19 | 2021-12-23 | 南京红云生物科技有限公司 | 取代喹唑啉类化合物、其制备方法、药物组合及应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6056684B2 (ja) | 1977-11-07 | 1985-12-11 | 東興薬品工業株式会社 | 点眼剤 |
US4271143A (en) | 1978-01-25 | 1981-06-02 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
US4407792A (en) | 1979-05-09 | 1983-10-04 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
US4615697A (en) | 1983-11-14 | 1986-10-07 | Bio-Mimetics, Inc. | Bioadhesive compositions and methods of treatment therewith |
US5041434A (en) | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
BR0015718A (pt) | 1999-11-22 | 2002-07-23 | Warner Lambert Co | Quinazolinas e seu uso para inibição de enzimas de cinase dependente de ciclina |
JP2006516561A (ja) | 2003-01-17 | 2006-07-06 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 細胞増殖の阻害剤としての2−アミノピリジン置換ヘテロ環類 |
JP2007509059A (ja) | 2003-10-16 | 2007-04-12 | カイロン コーポレイション | 癌の処置のためのRafキナーゼのインヒビターとしての、2,6−二置換キナゾリン、キノキサリン、キノリンおよびイソキノリン |
CA2567574C (en) | 2004-04-08 | 2013-01-08 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
NZ553492A (en) | 2004-08-25 | 2010-11-26 | Targegen Inc | Triazole derivatives and methods of use |
US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
US20060247250A1 (en) | 2005-03-16 | 2006-11-02 | Targegen, Inc. | Pyrimidine inhibitors of kinases |
EP1878727A4 (en) * | 2005-04-28 | 2013-11-13 | Kyowa Hakko Kirin Co Ltd | 2-AMINOQUINAZOLINE DERIVATIVES |
EP1893216A4 (en) | 2005-06-08 | 2012-08-08 | Targegen Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES |
PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
WO2008020203A1 (en) | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors |
TW200829566A (en) | 2006-12-08 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
KR20090092287A (ko) | 2006-12-22 | 2009-08-31 | 노파르티스 아게 | Pdk1 억제를 위한 퀴나졸린 |
US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
GB0719803D0 (en) * | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
US20100311965A1 (en) | 2007-12-28 | 2010-12-09 | Carna Biosciences Inc. | 2-aminoquinazoline derivative |
TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶,其組合物及使用其之治療方法 |
PE20120424A1 (es) | 2008-12-29 | 2012-05-04 | Fovea Pharmaceuticals | Compuestos de quinazolina sustituidos |
CA2751517A1 (en) * | 2009-02-13 | 2010-08-19 | Fovea Pharmaceuticals | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
-
2011
- 2011-06-21 TW TW100121689A patent/TW201204723A/zh unknown
- 2011-06-21 AR ARP110102137A patent/AR081960A1/es unknown
- 2011-06-22 MX MX2012015305A patent/MX2012015305A/es not_active Application Discontinuation
- 2011-06-22 NZ NZ605022A patent/NZ605022A/en not_active IP Right Cessation
- 2011-06-22 CN CN2011800407027A patent/CN103140480A/zh active Pending
- 2011-06-22 WO PCT/EP2011/060445 patent/WO2011161159A1/en active Application Filing
- 2011-06-22 SG SG2012094173A patent/SG186424A1/en unknown
- 2011-06-22 JP JP2013515883A patent/JP2013533237A/ja not_active Withdrawn
- 2011-06-22 PE PE2012002466A patent/PE20130640A1/es not_active Application Discontinuation
- 2011-06-22 UY UY0001033461A patent/UY33461A/es unknown
- 2011-06-22 BR BR112012032721A patent/BR112012032721A2/pt not_active IP Right Cessation
- 2011-06-22 AU AU2011268938A patent/AU2011268938A1/en not_active Abandoned
- 2011-06-22 MA MA35572A patent/MA34384B1/fr unknown
- 2011-06-22 CA CA2803496A patent/CA2803496A1/en not_active Abandoned
- 2011-06-22 KR KR1020137001581A patent/KR20130116070A/ko not_active Application Discontinuation
- 2011-06-22 US US13/805,479 patent/US20130123271A1/en not_active Abandoned
- 2011-06-22 EP EP11729591.5A patent/EP2585439A1/en not_active Withdrawn
- 2011-06-22 EA EA201291329A patent/EA201291329A1/ru unknown
-
2012
- 2012-12-18 IL IL223721A patent/IL223721A0/en unknown
- 2012-12-19 CR CR20120653A patent/CR20120653A/es unknown
- 2012-12-19 DO DO2012000317A patent/DOP2012000317A/es unknown
- 2012-12-19 TN TNP2012000610A patent/TN2012000610A1/en unknown
- 2012-12-20 NI NI201200193A patent/NI201200193A/es unknown
- 2012-12-20 GT GT201200345A patent/GT201200345A/es unknown
- 2012-12-21 CL CL2012003637A patent/CL2012003637A1/es unknown
- 2012-12-21 EC ECSP12012354 patent/ECSP12012354A/es unknown
- 2012-12-21 CO CO12231930A patent/CO6660505A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MA34384B1 (fr) | 2013-07-03 |
CA2803496A1 (en) | 2011-12-29 |
US20130123271A1 (en) | 2013-05-16 |
NZ605022A (en) | 2013-12-20 |
SG186424A1 (en) | 2013-01-30 |
KR20130116070A (ko) | 2013-10-22 |
CL2012003637A1 (es) | 2013-07-05 |
AR081960A1 (es) | 2012-10-31 |
JP2013533237A (ja) | 2013-08-22 |
CO6660505A2 (es) | 2013-04-30 |
EA201291329A1 (ru) | 2013-05-30 |
TW201204723A (en) | 2012-02-01 |
DOP2012000317A (es) | 2013-04-15 |
GT201200345A (es) | 2014-01-24 |
TN2012000610A1 (en) | 2014-04-01 |
ECSP12012354A (es) | 2013-01-31 |
WO2011161159A1 (en) | 2011-12-29 |
NI201200193A (es) | 2013-05-13 |
CN103140480A (zh) | 2013-06-05 |
CR20120653A (es) | 2013-04-03 |
UY33461A (es) | 2012-01-31 |
MX2012015305A (es) | 2013-05-30 |
AU2011268938A1 (en) | 2013-01-24 |
BR112012032721A2 (pt) | 2016-11-29 |
IL223721A0 (en) | 2013-03-05 |
EP2585439A1 (en) | 2013-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20130640A1 (es) | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica | |
HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
EA201300620A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ JAK | |
DOP2014000008A (es) | 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk | |
PE20141404A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
PE20171307A1 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
HRP20201165T1 (hr) | Uporaba inhibitora ccr3 | |
PE20090210A1 (es) | Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa | |
TN2013000275A1 (en) | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd) | |
PE20140408A1 (es) | Derivados espiro-oxindol como antagonistas de mdm2 | |
PE20170663A1 (es) | Compuestos de 5- cloro- 2- difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos | |
EA201291098A1 (ru) | Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ | |
PE20150623A1 (es) | Moduladores de la ruta del complemento y usos de los mismos | |
CR20130617A (es) | Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
ECSP13013024A (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
CR20130588A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2 | |
MX2013014007A (es) | [1,3] oxazinas. | |
PE20121815A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
PE20170003A1 (es) | Compuestos heterociclicos y usos de los mismos | |
MX2009010059A (es) | Derivados de quinolina para el tratamiento de enfermedades inflamatorias. | |
AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
EA201391752A1 (ru) | Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2 | |
MX2013011086A (es) | (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas. | |
PE20151601A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso | |
DOP2013000243A (es) | Inhibidores sustituidos de acetil-coa carboxilasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |